false000113872300011387232024-05-062024-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2024

ACCURAY INCORPORATED

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-33301

20-8370041

(Commission File Number)

(IRS Employer Identification No.)

1240 Deming Way

 

Madison, Wisconsin

 

53717-1954

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 608 824-2800

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

ARAY

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On May 6, 2024, Gina Corradetti provided Accuray Incorporated (the “Company”) with notice of her intent to resign from her position as VP, Chief Accounting Officer and principal accounting officer, which resignation will be effective May 17, 2024, to pursue other opportunities.

 

(c) On May 9, 2024, the Company’s Board of Directors appointed Ali Pervaiz, the Company’s Senior Vice President, Chief Financial Officer, to serve as the Company’s interim principal accounting officer, effective May 17, 2024 until a permanent successor is appointed.

 

Mr. Pervaiz, age 44, will continue to serve as the Company’s Senior Vice President and Chief Financial Officer, a position he has held since May 2022. Previously, Mr. Pervaiz served as the Company’s Vice President, Global Commercial Operations beginning August 2020. Prior to joining the Company, Mr. Pervaiz was with General Electric Healthcare (“GE Healthcare”), a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader focused on Margin Expansion for the Global Imaging business from September 2018 to January 2020 and Executive – Advance Leader focused on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previously held business unit Chief Financial officer roles at GE Healthcare for the US Commercial Diagnostic Imaging Equipment and US Commercial Life Support Solutions businesses. Mr. Pervaiz received an M.B.A. from the University of Chicago Booth School of Business with focus on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.

 

Mr. Pervaiz will not receive any additional compensation in connection with his appointment. Mr. Pervaiz has no family relationships or related party transactions with the Company that would require disclosure under Items 401(d) and 404(a) of Regulation S-K in connection with her appointment.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCURAY INCORPORATED

 

Dated: May 10, 2024

By:

/s/ Jesse Chew

Jesse Chew

Senior Vice President, Chief Legal Officer & Corporate Secretary

 

 

 

3


v3.24.1.1.u2
Document And Entity Information
May 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 06, 2024
Entity Registrant Name ACCURAY INCORPORATED
Entity Central Index Key 0001138723
Entity Emerging Growth Company false
Entity File Number 001-33301
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8370041
Entity Address, Address Line One 1240 Deming Way
Entity Address, City or Town Madison
Entity Address, State or Province WI
Entity Address, Postal Zip Code 53717-1954
City Area Code 608
Local Phone Number 824-2800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ARAY
Security Exchange Name NASDAQ

Accuray (NASDAQ:ARAY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Accuray 차트를 더 보려면 여기를 클릭.
Accuray (NASDAQ:ARAY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Accuray 차트를 더 보려면 여기를 클릭.